PBAC's latest decision on Lurbinectedin: Recommended with restriction (2025). Considered for First-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with atezolizumab for patients who have not progressed on or after first-line induction therapy with atezolizumab, a platinum-based antineoplastic drug, and etoposide.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults with extensive-stage small cell lung cancer who have not progressed after first-line induction therapy with atezolizumab, a platinum-based antineoplastic drug, and etoposide, with ECOG PS 0-1; excludes patients with central nervous system metastases.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Pivotal trial size
483 patients
Key trials
IMforte
Comparator
atezolizumab monotherapy
Economic model
CUA
ICER note
ICER value is redacted (represented as '****' in document)